Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(12):895-897; doi:10.1093/jnci/djh191
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Hayes, D. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayes, D. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

EDITORIAL

Tamoxifen: Dr. Jekyll and Mr. Hyde?

Daniel F. Hayes

Correspondence to: Daniel F. Hayes, MD, CCGC 6203, 1500 E. Medical Center Dr., Ann Arbor, MI 48109 (e-mail: hayesdf@umich.edu)

The first 150 words of the full text of this article appear below.

Without regard to patient selection, other than the eligibility requirements for entry into the studies, worldwide overviews of prospective clinical trials demonstrate that adjuvant tamoxifen reduces the annual odds of death for women with invasive breast cancer by approximately 15% over 10–15 years (1). These data raise the provocative question: Should all patients with invasive breast cancer receive tamoxifen? Application of tamoxifen, irrespective of selection factors, would result in overtreatment of an enormous number of women who would not benefit to ensure the benefits for those who do. Although acceptance of tamoxifen treatment is very high, the ability to measure its target, the estrogen receptor (ER), has permitted application of this drug to those most likely to benefit: patients whose tumors express ER (1,2). Thus, ER is one of the few tumor markers that is recommended for routine clinical use by the . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
D. Meijer, A. M Sieuwerts, M. P Look, T. van Agthoven, J. A Foekens, and L. C J Dorssers
Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer
Endocr. Relat. Cancer, March 1, 2008; 15(1): 101 - 111.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Cohen, B. Maly, I. Simon, A. Meirovitz, E. Pikarsky, E. Zcharia, T. Peretz, I. Vlodavsky, and M. Elkin
Tamoxifen Induces Heparanase Expression in Estrogen Receptor Positive Breast Cancer
Clin. Cancer Res., July 15, 2007; 13(14): 4069 - 4077.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M. Mc Ilroy, F. J Fleming, Y. Buggy, A. D K Hill, and L. S Young
Tamoxifen-induced ER-{alpha}-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence
Endocr. Relat. Cancer, December 1, 2006; 13(4): 1135 - 1145.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. M. Sieuwerts, M. E. Meijer-van Gelder, M. Timmermans, A. M.A.C. Trapman, R. R. Garcia, M. Arnold, A. J.W. Goedheer, H. Portengen, J. G.M. Klijn, and J. A. Foekens
How ADAM-9 and ADAM-11 Differentially From Estrogen Receptor Predict Response to Tamoxifen Treatment in Patients with Recurrent Breast Cancer: a Retrospective Study
Clin. Cancer Res., October 15, 2005; 11(20): 7311 - 7321.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. P.H.M. Jansen, J. A. Foekens, I. L. van Staveren, M. M. Dirkzwager-Kiel, K. Ritstier, M. P. Look, M. E. Meijer-van Gelder, A. M. Sieuwerts, H. Portengen, L. C.J. Dorssers, et al.
Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling
J. Clin. Oncol., February 1, 2005; 23(4): 732 - 740.
[Abstract] [Full Text] [PDF]